Hemlibra 105mg Injection

Introduction

Hemlibra is a prescription medication that contains the active ingredient Emicizumab. It is also known by its generic name, Emicizumab. This medication is primarily used for the treatment of a specific type of hemophilia called hemophilia A with factor VIII inhibitors.

Uses

Hemlibra is prescribed for individuals with hemophilia A who have developed inhibitors to factor VIII, which is a clotting protein. This medication helps to prevent or reduce bleeding episodes in patients with this specific type of hemophilia.

Dosage and Administration

The dosage of Hemlibra will be determined by your healthcare provider based on factors such as your body weight and specific medical condition. It is usually administered once weekly, subcutaneously (under the skin), after proper training and instruction from your healthcare provider. Follow the dosage instructions provided by your healthcare professional and not to change the dosage without consulting them first.

Mechanism of Action

Hemlibra works by mimicking the function of factor VIII, which is necessary for normal blood clotting. It acts as a bispecific antibody that brings together activated factor IX and factor X, bypassing the need for factor VIII in the clotting process. This helps to promote blood clotting and prevent bleeding episodes in individuals with hemophilia A with factor VIII inhibitors.

Side Effects

Common side effects may include injection site reactions, headache, joint pain, and fever. These side effects are usually mild and temporary. However, if you experience any of the following serious side effects, seek medical attention immediately:

• Allergic reactions, such as rash, itching, swelling, or difficulty breathing
• Signs of blood clots, such as sudden severe headache, chest pain, shortness of breath, or swelling in the arms or legs
• Signs of bleeding, such as unusual bruising, prolonged bleeding from cuts, or blood in urine or stool

Drug Interactions

inform your healthcare provider about all the medications you are taking, including prescription drugs, over-the-counter medications, and herbal supplements. Some medications may interact with Hemlibra, potentially affecting its effectiveness or increasing the risk of side effects. Common drug interactions may include certain anticoagulants or antiplatelet medications. Discuss any potential drug interactions with your healthcare provider before starting Hemlibra.

Precautions

Before using Hemlibra, inform your healthcare provider about any medical conditions or allergies you have. This medication may not be suitable for individuals with a history of blood clots. Avoid any activities that may increase the risk of bleeding or injury while using this medication. Additionally, discuss with your healthcare provider any other medications or substances you are currently using to avoid potential interactions.

Storage

Hemlibra should be stored in the refrigerator between 2°C and 8°C (36°F and 46°F). Do not freeze the medication. Keep it in the original packaging and protect it from light. Discard any unused medication according to your healthcare provider’s instructions.

Patient Tips

• Make sure you receive proper training and instruction from your healthcare provider on how to self-administer Hemlibra.
• Follow the recommended dosing schedule provided by your healthcare provider.
• If you miss a dose, contact your healthcare provider for guidance.
• Inform your healthcare provider about any unusual or persistent side effects you experience.
• Carry a medical alert card or wear a medical alert bracelet to inform others about your condition and the medication you are taking.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Hemlibra 150 mg/mL Solution for Injection (Health Professionals SmPC) Available at:
• Emicizumab (Drugs.com) [Accessed 14 Jun. 2024] (online) Available at:
• emicizumab-kxwh 30 mg/ml subcutaneous solution (RX) [Accessed 23 Jun. 2024] (online) Available at:
• Emicizumab-kxwh Injection (MedlinePlus) [Accessed 19 Jun. 2024] (online) Available at:
• Mahlangu J, Iorio A, Kenet G. Emicizumab state-of-the-art update. Haemophilia. 2022 May;28 Suppl 4(Suppl 4):103-110. doi: 10.1111/hae.14524. [Accessed 1 Jun. 2024] Available at: